Alumis’ (ALMS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alumis (NASDAQ:ALMS) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $26.00 price target on the stock.

A number of other equities research analysts have also recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Baird R W upgraded Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Finally, Robert W. Baird started coverage on shares of Alumis in a research note on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target on the stock. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $26.83.

Alumis Trading Up 4.0 %

ALMS opened at $8.79 on Monday. Alumis has a one year low of $7.46 and a one year high of $13.53. The business’s fifty day moving average price is $9.48.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. SR One Capital Management LP acquired a new stake in shares of Alumis in the second quarter valued at about $26,067,000. Charles Schwab Investment Management Inc. purchased a new position in Alumis in the 3rd quarter valued at about $1,160,000. Towerview LLC grew its stake in Alumis by 22.6% during the 3rd quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after purchasing an additional 70,000 shares in the last quarter. State Street Corp purchased a new stake in Alumis during the 3rd quarter worth approximately $866,000. Finally, Stifel Financial Corp acquired a new position in shares of Alumis in the 3rd quarter valued at approximately $931,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.